This clinical benefit can be mainly attributed to selective treatment with futibatinib among patients with FGFR2 aberrations leading to the effective abrogation of FGFR-dependent downstream signalling, which promotes cellular proliferation and survival, resulting in potent anti-tumour activity. The gene discussed is FGFR2; the disease is neoplasm.